The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
 
Sham Mailankody
Honoraria - Physicans' Education Resource; Weber Shandwick
Research Funding - Alimera Sciences (Inst); Alimera Sciences (Inst); Alimera Sciences (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Takeda (Inst)
 
Andrzej J. Jakubowiak
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics
Travel, Accommodations, Expenses - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics
 
Myo Htut
No Relationships to Disclose
 
Luciano J. Costa
Honoraria - Amgen; Celgene; Janssen
Consulting or Advisory Role - Abbvie; Amgen; Celgene; Karyopharm Therapeutics
Speakers' Bureau - Amgen; Sanofi
Research Funding - Amgen; Janssen
 
Kelvin Lee
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Siddhartha Ganguly
Honoraria - Kite, a Gilead company; Seagen
Speakers' Bureau - Kite, a Gilead company; Seagen
Research Funding - Daiichi Sankyo (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; Seagen
 
Jonathan L. Kaufman
Honoraria - Tecnofarma
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda; Tecnofarma; TG Therapeutics
Research Funding - Abbvie/Genentech (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Fortis (Inst); Janssen (Inst); Merck (Inst); Sutro Biopharma (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Sanofi; Takeda
 
David Samuel DiCapua Siegel
Stock and Other Ownership Interests - Celularity
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Karyopharm Therapeutics; Merck; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Takeda
Research Funding - Celgene (Inst)
 
William Bensinger
Honoraria - Amgen; Celgene; Janssen; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda
Research Funding - Acetylon Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Merck; Sanofi
Expert Testimony - Celgene; Takeda
 
Mariana Cota
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Doerr
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Todd DeVries
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sandy Wai Kuan Wong
Consulting or Advisory Role - Amgen
Research Funding - Bristol-Myers Squibb; Fortis; Genentech; Janssen